Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Siponimod in Secondary Progressive Multiple Sclerosis (Japan, Phase 3)
jRCT2080222397Phase 3Completed
- Sponsor
- Novartis
- Start
- Feb 2014
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in secondary-progressive multiple sclerosis (SPMS) comparing Siponimod with Placebo (2 arms). Started Feb 2014; status: completed.
02
Drugs
siponimod
03
Conditions
secondary-progressive multiple sclerosis (SPMS)
Beyond the preview
Go deeper on jRCT2080222397.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222397.